OrigAMI-2: Amivantamab + Chemotherapy Versus Cetuximab + Chemotherapy in Treatment-naïve Participants with KRAS/NRAS and BRAF Wild-type Colorectal Cancer
Condition: Colorectal Cancer
Sponsor: Janssen Research & Development, LLC
Full Title
Protocol 61186372COR3001: A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Study Treatment
EGFRxMET bispecific antibody Amivantamab vs Cetuximab
Given in combination with either FOLFOX or FOLFIRI chemotherapy
Eligibility/Info
KRAS, NRAS, and BRAF wild type unresectable or metastatic left sided colorectal cancer that has not previously been treated with systemic therapy in the metastatic setting.
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
